Skip to content
DataLookout
Menu

NCT06980272

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

StatusTerminated
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Sponsor decided Show 5 more changesShow less
    • Final enrollment: 3 participants, 1% of the 420 planned
    • Eligibility criteria expanded, about 17 words
    • Primary completion date changed from estimate of Jul 30, 2026 to Feb 1, 2026
    • Study completion date changed from estimate of Dec 31, 2028 to Mar 1, 2026
    • Site details revised
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 25, 2025 to Jun 20, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

PFS assessed by IRRC per RECIST v1.1
Timeframe: Up to 2 approximately years

Secondary (13)

OS
ORR assessed by IRRC per RECIST v1.1
DoR assessed by IRRC per RECIST v1.1
DCR assessed by IRRC per RECIST v1.1
TTR assessed by IRRC per RECIST v1.1
Show 8 moreShow less
PFS assessed by investigator per RECIST v1.1
ORR assessed by the investigator per RECIST v1.1
DoR assessed by the investigator per RECIST v1.1
DCR assessed by the investigator per RECIST v1.1
TTR assessed by the investigator per RECIST v1.1
AE
ADA
PD-L1 expression

Arms and interventions

SSGJ-707Experimental

Subjects receive SSGJ-707 monotherapy intravenously (IV), selected dose.

PembrolizumabActive comparator

Subjects receive Pembrolizumab monotherapy intravenously (IV), 200mg q3w.

Drugs: SSGJ-707, Pembrolizumab

Sites

1 site in 1 country

  • The Shanghai East HospitalShanghai, China